Abstract Varicella zoster virus (VZV) vasculopathy is caused by productive virus infection of cerebral arteries, leading to inflammation, pathological vascular remodeling, and ischemic or hemorrhagic stroke. VZV vasculopathy occurs in immunocompetent and immunocompromised individuals and involves both large and small vessels. MRI abnormalities include more deep-seated than superficial lesions, particularly at gray-white matter junctions, and lesions may enhance. Diagnosis is challenging, since stroke can occur months after zoster rash and in the absence of rash or CSF pleocytosis. The best virological test for diagnosis is detection of anti-VZV IgG antibody in the CSF. Pathological studies of VZV-infected arteries from patients with VZV vasculopathy reveal that the arterial adventitia is the initial site of infection, after which virus spreads transmuraly towards the lumen. Histological and immunohistochemical studies of VZV-infected arteries show a thickened intima, disrupted internal elastic lamina, and loss of smooth muscle cells, that likely contribute to weakening of the vessel wall and occlusion. Early in disease, VZV-infected arteries contain CD4+ and CD8+ T cells, macrophages, and rare B cells, in addition to abundant neutrophils in early disease. Importantly, perivascular inflammatory cells underlie the areas of thickened intima, raising the possibility that soluble factors secreted by these cells contribute to arterial remodeling. This review discusses the clinical features of VZV vasculopathy and potential mechanisms of VZV-induced cerebrovascular remodeling and stroke.
Introduction
Varicella zoster virus (VZV) is a ubiquitous, exclusively human, double-stranded DNA alpha-herpesvirus. Primary VZV infection causes varicella (chickenpox), after which virus becomes latent in cranial nerve ganglia, dorsal root ganglia, and autonomic ganglia along the entire neuraxis (Hyman et al. 1983; Gilden et al. 1983; Mahalingam et al. 1990; Kennedy et al. 1998; Gilden et al. 2001) . With a decline in VZV cellmediated immunity from age or immunosuppression, VZV may reactivate to cause herpes zoster (shingles), which is often complicated by chronic pain (postherpetic neuralgia), cranial nerve palsies, zoster paresis, vasculopathy, meningoencephalitis, cerebellitis, myelopathy, and multiple ocular disorders (reviewed in Gilden et al. 2010) . VZV reactivation also produces chronic radicular pain without rash (zoster sine herpete). In fact, all neurological complications of VZV reactivation can occur without rash.
Historically, VZV vasculopathy was described as acute hemiplegia after contralateral zoster in adults or as postvaricella arteriopathy in children, with primary involvement of large vessels. In the past few decades, the clinical spectrum of VZV vasculopathy has expanded and now includes transient ischemic attacks, ischemic and hemorrhagic infarcts, aneurysm, cerebral and subarachnoid hemorrhage, and arterial ectasia with involvement of both large and small vessels (reviewed in Gilden et al. 2009 ). More recently, elderly patients with multifocal VZV vasculopathy and temporal artery infection were shown to have clinical and laboratory features similar to those of patients with giant cell arteritis (Nagel et al. 2013b ), a vasculitis of unclear etiology which can cause vision loss. The presence of VZV DNA, VZV antigen, herpesvirus particles, Cowdry A inclusions, and multinucleated giant cells in arteries from a patient who died of chronic protracted VZV vasculopathy provided direct evidence for the role of VZV in stroke (Gilden et al. 1996) .
In adults, VZV vasculopathy is reported more commonly in immunocompromised than in immunocompetent individuals.
Before the availability of antiretroviral therapy, CNS infection caused by VZV was detected in 1.5 to 4.4 % of autopsy cases among HIV-infected patients with documented vasculopathy (Morgello et al. 1988; Gray et al. 1992 Gray et al. , 1994 and leukoencephalitis (Gray et al. 1992 (Gray et al. , 1994 Petito et al. 1986; Ryder et al. 1986 ); most of these cases occurred in patients with severe CD4 T cell depletion. In addition, adults with zoster have an attendant 31 % increase in the risk of stroke in the following year (Kang et al. 2009 ); zoster in the ophthalmic distribution of the trigeminal nerve further increases the stroke risk 4.5-fold (Lin et al. 2010 )-suggesting either a direct or indirect role of VZV infection in stroke. In children, 31 % of all arterial ischemic strokes and 44 % of transient cerebral arteriopathy is associated with varicella (Askalan et al. 2001; Braun et al. 2009 ). Herein, I review findings on the clinical and laboratory features of VZV vasculopathy, as well as pathology and potential mechanisms of VZV-induced cerebrovascular remodeling leading to stroke.
Clinical, imaging, and laboratory features of VZV vasculopathy VZV vasculopathy can present with or without rash and produces clinical features and imaging, angiographic, and CSF abnormalities similar to those of other vasculitides. Analysis of 30 patients with VZV vasculopathy as confirmed by detection of either VZV DNA or anti-VZV IgG antibody in CSF (Nagel et al. 2008) identified characteristic features of the disease. Of these 30 patients, 63 % had rash, 67 % had a CSF, pleocytosis, and 97 % had brain imaging abnormalities. MRI abnormalities include more deep-seated than superficial lesions, particularly at gray-white matter junctions and lesions that enhanced. Angiography revealed arterial stenosis in 70 % of patients. Both large and small arteries were involved in 50 % of patients, while small arteries were involved exclusively in 37 % and large arteries exclusively in 13 %. The average time from rash to neurologic symptoms and signs was 4.1 months, and average time from neurologic symptoms and signs to CSF virologic confirmation was 4.2 months. Approximately 67 % of the patients stabilized or improved with intravenous acyclovir.
Diagnosis of VZV vasculopathy
VZV vasculopathy should be suspected in patients with a recent history of herpes zoster or varicella who present with a transient ischemic attack, ischemic or hemorrhagic stroke, or altered mental status. This diagnosis should also be considered in patients with a stroke of unknown origin, particularly among HIV+ and immunocompromised patients. The absence of rash should not deter the clinician from pursuing a diagnostic evaluation for VZV vasculopathy, since 37 % of patients may not have rash (Nagel et al. 2008 ).
Confirmatory laboratory diagnosis of VZV vasculopathy is made by the presence of VZV DNA or anti-VZV antibody in the CSF. Of 30 patients with VZV vasculopathy, only 30 % had VZV DNA in CSF; in contrast, 93 % had anti-VZV IgG antibody in CSF with a reduced serum/CSF ratio of anti-VZV IgG that confirmed intrathecal synthesis of anti-VZV IgG (Nagel et al. 2008) . Thus, detection of anti-VZV IgG in CSF has higher sensitivity than detection of VZV DNA in CSF, most likely due to the protracted nature of the disease (Nagel et al. 2007 ).
Multifocal VZV vasculopathy with temporal artery infection
Recently, we encountered three patients with a novel variant of multifocal VZV vasculopathy with temporal artery infection (Salazar et al. 2011; Nagel et al. 2013a; Mathias et al. 2013) . All three patients presented with ischemic optic neuropathy and one patient also developed acute retinal necrosis early (Mathias et al. 2013) . VZV infection of the ipsilateral temporal artery was detected in all three patients. Importantly, these patients experienced symptoms, signs, and laboratory abnormalities characteristic of giant cell arteritis (GCA), a vasculitis of unclear etiology that is treated with corticosteroids; yet histopathological exam of the patients' temporal arteries was negative for GCA. Thus, patients with suspected GCA, but whose arteries are pathologically negative for GCA, may have multifocal VZV vasculopathy with temporal artery infection. It is essential to differentiate GCA from multifocal VZV vasculopathy, since treatment with corticosteroids for presumed GCA may potentiate VZV infection and lead to loss of vision. In contrast, patients with multifocal VZV vasculopathy require immediate antiviral treatment.
To further address the frequency of VZV infection in GCA biopsy-negative patients, we conducted immunohistochemical analysis for the presence of VZV antigen in 24 temporal arteries from patients with clinically suspected GCA, but whose biopsies were negative (Nagel et al. 2013b ). Temporal Fig. 1 VZV antigen in biopsy negative temporal arteries from subjects with clinically suspected giant cell arteritis positive control VZV-infected cadaveric human cerebral artery (A, arrows) shows VZV antigen (pink color). Five (21 %) of 24 subjects with suspected GCA, but whose temporal arteries were pathologically GCA-negative, contained VZV antigen. Subjects 1 and 2 had VZV antigen exclusively in the adventitia (C and F respectively, arrows). Subject 3 had VZV antigen exclusively in the media (I, arrows). Subject 4 had VZV antigen in the media (L, thick arrow) and in the intima (L, arrowhead) adjacent to the internal elastic lamina (L, thin arrow). Subject 5 had VZV antigen exclusively in the media (O, thick arrow) adjacent to the internal elastic lamina (O, thin arrow). HSV-1 antigen was present in the positive control HSV-1-infected cadaveric cerebral artery (B, arrows), but not in any human temporal arteries, including those that contained VZV antigen (D, G, J, M, and P). No staining was seen, when NRS was used as primary antibody (E, H, K, N, and Q). None of 13 temporal arteries from 7 normal subjects contained VZV antigen (data not shown). Magnification ×600. Reproduced from Nagel et al. 2013a, b, c, d , with permission from Neurology b arteries from five patients (21 %) contained VZV (Fig. 1) ; all five subjects presented with clinical and laboratory features of GCA and early visual disturbances. In contrast, 13 normal temporal arteries did not contain VZV antigen. Overall, multifocal VZV vasculopathy can present with the full spectrum of clinical features and laboratory abnormalities characteristically seen in GCA.
Pathogenesis

Histology and immunohistochemical analyses
No animal model exists for stroke caused by VZV infection of cerebral arteries. To identify features that might help in diagnosis and lead to a better understanding of VZV-induced cerebrovascular remodeling, we analyzed cerebral and temporal arteries from three patients with VZV vasculopathy (Nagel et al. 2008) . Histological and immunohistochemical analysis using antibodies directed against VZV, endothelium, and smooth muscle actin and myosin indicated the presence of VZV antigen in the outermost layer of the artery (adventitia) early in infection and in the media and intima later (Fig. 2) , a finding consistent with transaxonal spread of reactivated VZV to the arterial adventitia followed by transmural spread of virus ). In addition, virus-infected arteries revealed: (1) a disrupted internal elastic lamina (Fig. 2) , (2) a thickened intima (Fig. 2) composed of cells expressing alphasmooth muscle actin and smooth muscle myosin heavy chain, but not endothelial cells expressing CD31, and (3) decreased numbers of medial smooth muscle cells ). The loss of medial smooth muscle cells and the presence of cells expressing myosin in the thickened intima suggest that some of these cells may be of medial smooth muscle origin. Overall, stroke in VZV vasculopathy may result from changes in arterial caliber and contractility produced in part by abnormal Fig. 2 Histologic and virological analyses of arteries from subjects with VZV vasculopathy Hematoxylin & eosin (H&E) stain of an uninfected middle cerebral artery from subject 3 (A) shows normal artery morphology; Verhoeff-Van Gieson (VVG) staining shows an intact internal elastic lamina (E, arrow) devoid of VZV antigen (I). In the temporal artery of subject 1 with early VZV vasculopathy, as well as the right middle cerebral artery of subjects 2 and 3 (both of whom died of protracted VZV vasculopathy), H&E staining reveals a hyperplastic intima in all three arteries (B-D, vertical black lines), and VVG staining shows duplication or frank disruption of the internal elastic lamina in the arteries of all three subjects with VZV vasculopathy (F-H, arrows) . VZV antigen (pink) in seen in the adventitia of subject 1 at 4 weeks after zoster (J, arrow), in the media of subject 2 (without a history of zoster rash) after a 45-week duration of VZV vasculopathy (K, arrow), and in the hyperplastic intima of subject 3 at 48 weeks after zoster (L, arrow). Magnification ×100 in panels A-H and ×600 in panels I-L. Reproduced from Nagel et al. 2011 , with permission from Neurology accumulation of smooth muscle cells and myofibroblasts in the thickened neointima and by disruption of the media associated with the presence of viral antigen.
In a related study to determine the frequency of VZVantigen in the arteries of normal subjects, we analyzed 63 human cerebral arteries from 45 subjects for VZV DNA and antigen, control herpes simplex virus (HSV)-1 DNA and antigen, and leukocyte-specific CD45 antigen (Nagel et al. 2013c) . No cerebral arteries contained VZVor HSV-1 DNA or antigen, while eight arteries from seven subjects contained CD45+ leukocytes. Thus, the presence of VZV antigen in cerebral arteries of patients with stroke is likely to be clinically significant.
Immune characteristics of VZV-infected arteries
Pathologic changes in VZV-infected arteries include inflammation, a thickened intima, and a paucity of smooth muscle cells. Since no criteria have been established for early versus late VZV vasculopathy, we examined inflammatory cells and their distribution in six normal cerebral arteries and in two VZV-infected arteries at 3 days after onset of disease (early) and at 10 months after protracted neurologic disease (late) (Nagel et al. 2013d ). Immunohistochemical analysis revealed VZV antigen in the adventitia of early disease and in the media of late disease. In addition, arteries contained CD4+ and CD8+ T cells, CD68+ macrophages, and rare B cells, expressing CD20 distributed in the adventitia and intima but not the media. Early VZV vasculopathy was distinguished by the presence of abundant neutrophils in the adventitia, which were absent in late VZV vasculopathy. In late VZV vasculopathy, viral antigen was seen in the media in the absence of leukocytes, supporting the notion that the media is an immunoprivileged site (Dal Canto et al. 2001) . Inflammatory cells were absent in control arteries.
The presence of neutrophils in the arterial adventitia in early VZV vasculopathy is consistent with their presence in the CSF of patients with neurological disease due to VZV (Stevens et al. 1975; Devinsky et al. 1991; Gilden et al. 1994; Amlie-Lefond et al. 1995; Gilden et al. 1996; Haug et al. 2010) . Although the mechanisms of vascular remodeling triggered by VZV are unknown, neutrophils may play a role. When exposed to VZV, neutrophils produce reactive oxygen species which may mediate smooth muscle cell proliferation and migration (Weber et al. 2004; Hartney et al. 2011 ) and induce apoptosis and loss of vascular smooth muscle cells (Hsieh et al. 2001; Li et al. 2003) . Neutrophils also secrete elastase, which can lead to extracellular matrix breakdown and weakening of the vessel wall (Okada and Nakanishi 1989; Itoh and Nagase 1995; Ferry et al. 1997 ). Finally, a thickened intima was associated with inflammation in vasa vasorum vessels in early VZV vasculopathy (Fig. 3) , consistent with a role for virus-induced inflammation in vessel wall remodeling (Frid et al. 2006; Stenmark et al. 2012) .
Conclusion
VZV vasculopathy is a potentially treatable cause of stroke and should be suspected in patients with zoster or varicella followed by transient ischemic attacks, stroke, or altered mental status. It is important to recognize that the absence of rash or a CSF pleocytosis or VZV DNA in CSF does not exclude the diagnosis, particularly in immunosuppressed individuals. Characteristic features include imaging and angiographic abnormalities involving both large and small vessels. The best test for diagnosis is detection of anti-VZV IgG in the CSF. Treatment consists of intravenous acyclovir. Histological and immunohistochemical studies of VZV-infected arteries from patients with VZV vasculopathy point to morphological changes such as a thickened intima and paucity of smooth muscle cells, which can potentially lead to ischemia and aneurysm formation and hemorrhage, respectively . Furthermore, the finding of inflammation in association with a thickened intima in a VZV-infected artery supports cardio-and pulmonary vascular evidence that inflammation is intimately involved in vascular remodeling, perhaps through the release of soluble factors that contribute Fig. 3 In early VZV vasculopathy, the thickened intima is associated with inflammatory cells in the vasa vasorum within the adventitia of arteries in early VZV vasculopathy artery, two vasa vasorum vessels contained T cells expressing CD3 (long black arrows, brown color) adjacent to the thickened intima (black bars). Short black arrows in areas where the intima is not thickened were devoid of cells expressing CD3. A thickened intima was also associated with cells expressing CD4, CD8, CD20, and CD68 (not shown). Magnification ×100. Reproduced from Nagel et al., 2013a, b, c, d , with permission from Neurology to pathological vessel remodeling. Further studies on more human arteries are needed to dissect the mechanism(s) of VZV vasculopathy.
